Tafalgie Therapeutics, a biopharmaceutical research company specializing in research and innovation for treatments to alleviate and prevent acute and chronic pain (inflammatory, postoperative, neuropathic) without side effects is proud to announce that it has been selected for the ‘IPOready’ 2024 program, which aims to support fast-growing European companies that may subsequently be listed on Euronext.

Tafalgie Therapeutics and its management team will therefore have access to all the tools and information required to accelerate their development for the possible establishment of an IP process in coming years.

Tafalgie Therapeutics will participate in this program alongside more than 160 companies from 15 European countries this year. This figure testifies to the dynamism of a pool of ambitious, fast-growing companies considering a European listing, and the relevance of Euronext as Europe’s leading listing platform.